DALLAS--(BUSINESS WIRE)--HemoBioTech, Inc. (OTCBB: HMBT, http://www.hemobiotech.com) a biopharmaceutical company focused on developing and commercializing the fist viable human blood substitute with their bovine hemoglobin-based solution, HemoTech, provides an update on recent media and financial news.
